GWPH - GW Pharmaceuticals plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
126.49
-2.43 (-1.88%)
At close: 4:00PM EDT

126.49 0.00 (0.00%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close128.92
Open133.50
Bid126.58 x 1100
Ask126.59 x 1300
Day's Range125.25 - 133.50
52 Week Range90.14 - 196.00
Volume910,792
Avg. Volume453,644
Market Cap3.873B
Beta (3Y Monthly)2.09
PE Ratio (TTM)N/A
EPS (TTM)-3.29
Earnings DateOct 1, 2019 - Oct 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est227.31
Trade prices are not sourced from all markets
  • This Biotech Stock Flies High After CBD Oil Gains Approval In Europe
    Investor's Business Daily

    This Biotech Stock Flies High After CBD Oil Gains Approval In Europe

    GW Pharmaceuticals stock popped early Monday after the European Medicine Agency approved the biotech company's cannabidiol oil, a medicine called Epidyolex, in two seizure disorders.

  • Bruker (BRKR) Enters Into Alliance With Murdoch University
    Zacks

    Bruker (BRKR) Enters Into Alliance With Murdoch University

    Bruker's (BRKR) collaboration with Murdoch University will support International Centre of Excellence in metabolic phenotyping.

  • Benzinga

    GW Pharma's CBD Seizure Drug Epidiolex Approved In Europe As Adjunctive Therapy

    GW Pharma said the European Commission has approved the marketing authorization for Epidiolex as an adjunctive therapy of seizures associated with Lennox-Gastaut syndrome, or LGS, or Dravet syndrome, or DS, in conjunction with clobazam, for treating patients two years of age and older.

  • Cannabis Industry to Scale New Highs Amid Legalization Woes
    Zacks

    Cannabis Industry to Scale New Highs Amid Legalization Woes

    Legalization will likely drive commercial distribution of cannabis and boost growth of companies operating in this space.

  • MarketWatch

    UPDATE: GW Pharma gets EU approval for cannabis-based drug as treatment for severe childhood epilepsy

    GW Pharmaceuticals PLC shares rose 3.9% in premarket trade Monday, after the company said it has received European Commission approval for its cannabis-based drug Epidyolex for the treatment of seizures in patients with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, two severe types of childhood epilepsy. The drug, which is already approved in the U.S. under the brand name Epidiolex, will now be available to children of 2 years of age and older across Europe. The news "marks a significant milestone, offering patients and their families the first in a new class of epilepsy medicines and the first and only EMA-approved CBD medicine to treat two severe and life-threatening forms of childhood-onset epilepsy," Chief Executive Justin Gover said in a statement. The approval is based on the results from four randomised, controlled phase 3 trials, involving more than 714 patients. GW Pharma shares have gained 32% in 2019, while the S&P 500 has gained 19%.

  • GlobeNewswire

    GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

    GW Pharmaceuticals plc (GWPH) (“GW”, “the Company” or “the Group”), world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces that the European Commission (EC) has approved the marketing authorisation for EPIDYOLEX® for use as adjunctive therapy of seizures associated with Lennox‑Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older. The approval paves the way for the launch of the medicine across Europe.

  • 3 Cannabis Stocks Poised for Gains in the US CBD Market
    TipRanks

    3 Cannabis Stocks Poised for Gains in the US CBD Market

    The greatest barrier to the full exploitation of the cannabis market in the US is the patchwork quilt of various legalization regimes in the country. Cannabis is fully illegal in 9 states, fully legal in 11, and subject a variety of laws in the remaining 30. Some states permit medical use, some permit medical use of CBD extracts only, while others have partially decriminalized it. At the Federal level, marijuana remains fully illegal as a Schedule 1 Controlled Substance, but the closely related hemp plant was fully legalized at the Federal level by the 2018 Farm Bill.The legalization of hemp opens exciting prospects for cannabis in the US. Aside from its industrial uses – hemp can be used in the manufacture rope, fabrics, and paper, to name just a few – the plant is a major source of cannabidiol extracts, the CBDs that are quickly becoming popular in medicinal use. CBD, being legal, is starting to take off in the marketplace, and those cannabis companies with a focus on this non-psychoactive compound will find themselves well-positioned to take off with it.And they are sure to take off - a study by BDS Analytics predicts the CBD market reaching $20 billion annually by 2024. BDS' Jessica Lukas sees the market expanding across a variety of categories in the next near future, including food, candy, beverages, and skin and beauty. She says, "While dispensaries and e-commerce drive the majority of cannabinoid sales today in the US, this shifts versus the next five years."We’ve delved into TipRanks’ database to find three companies that are ready to gain on CBD. Aphria, Inc.Aphria (APHA – Get Report) astounded the markets back in early August, with a C$20 million top-line beat in the quarterly report, and better yet, a quarterly profit of C$15.8 million. The profit line represented a C$29.7 million beat – the forecast had been for a C$13.9 million net loss. It was an impressive quarter for the third-largest producer in the global cannabis markets.Aphria offers investors two other important features, besides a turn to profitability. First, the stock is available at a low price, just $6.16 on the New York market. And second, Aphria has leveraged its scale into partnerships with the US CBD markets. Aphria’s CBD products are based on marijuana-derived hemp, so the Canadian-based company faced trade hurdles in addition to the legal patchwork in the States – but a shift to hemp-based product, or Federal legalization of CBD, will put Aphria in a strong position to expand its operations quickly.Writing of the company just after the quarterly report, Canaccord Genuity analyst Matthew Bottomley described the “solid rebound in cannabis revenues” as a “pleasant surprise,” and went on to note that increased efficiency in packaging and distribution had improved gross margins. Backing up his buy rating and $12 price target, Bottomley wrote, “Although we were discouraged in the previous quarter, we believe Aphria’s strong FQ4 indicates that the company is still competing for a top-three spot in the Canadian cannabis market.” His price target suggests a robust 95% upside for Aphria.More recently, 3-star analyst Justin Keywood, of GMP FirstEnergy, initiated coverage of APHA. He was impressed enough by the stock to start it with a buy rating and a price target of $10.50. His target suggests an upside potential of 71%.APHA’s consensus rating is a Moderate Buy, based on 4 reviews from the past three months. The reviews include 2 buys, 1 hold, and 1 sell. APHA shares sell for $6.16, and the average price target of $7.79 indicates a 26% potential upside for the stock. Charlotte’s Web Holdings, Inc.Most of the big cannabis companies are Canadian-based, logical since was the first country in North American to introduce full legalization. Charlotte’s Web (CWBHF – Get Report), based in Boulder, Colorado, is the exception. It’s an exception that proves the rule, however, as Colorado was one of the first US jurisdictions to fully legalize marijuana at the State level.Charlotte’s Web’s main products are based on CBD extracts and include CBD and hemp oils, capsules, and edible gummies. The company even markets products for pets – they have a hemp extract designed for dogs. Since the products are derived from legal hemp-extracted CBD, Charlotte’s Web has a marketing advantage over most competitors: large, established chains are willing to carry the products. Kroger (KR – Get Report) and CVS (CVS – Get Report) both carry Charlotte’s Web CBD products as over-the-counter pharmaceuticals.A rough fiscal second quarter did not stop analysts from giving strong ratings to CWBHF. Jason Zandberg, a 4-star analyst with PI Financial, reiterated his buy rating and $22 price target last month. He noted, “hemp supply will not be an issue for CWEB in the foreseeable future, as the company planted 862 acres in 2019, a 187 per cent increase from the 300 acres planted in 2018.” Looking at the financial forecast, Zandberg wrote, “Management maintains revenue guidance of between $120 million and $170... The range is dependent on the FDA providing positive regulations for hemp-derived CBD in 2019. While we believe that the FDA will eventually do this, our expectation is that it will not happen this year.” Zandberg’s price target is based on this optimistic scenario, and implies an upside of 35% to the shares.Piper Jaffray’s Michael Lavery was also impressed by CWBHF, enough to start his coverage of the company with a buy rating and a $25 price target. His target indicates confidence in a 49% for CWBHF.Overall, Charlotte’s Web has a Strong Buy consensus rating, based on 3 buys assigned in the past three months. The stock’s $23 average price target suggests an upside of 38% from the $16.75 current share price. GW Pharmaceuticals, Inc.With GW Pharma (GWPH – Get Report) we get to a cannabis company that is also a mainstream stock. GW is a long-established biotech firm, originally founded as an early adopter in the cannabis industry. GW has two cannabis-derived drugs on the open market: Sativex, a treatment for the symptoms of multiple sclerosis, and Epidiolex, a treatment for epilepsy associated with Dravet Syndrome in children. Epidiolex was approved by the US FDA in 2018.Standing squarely where the cannabis industry meets the pharmaceutical business, GW Pharma benefits from having two approved drugs to market. While the company operates with a net loss (not uncommon in either the cannabis or pharmaceutical fields), the August quarterly report continued a four-quarter run of improving earnings. The reported loss of 78 cents per share was a 55% improvement over the expected EPS loss of $1.74.Wall Street has high expectations for GW Pharma. Predictions are, the company will grow more than 90% in fiscal 2019, and turn to profits in 2020. Rosy prospects have prompted analysts to raise more than just expectations – Stifel’s 5-star analyst Paul Matteis raised his price target to $228 in his recent review of the stock. His new target implies an impressive upside of 76%. Oppenheimer’s Esther Rajavelu is even more optimistic, increasing her target to $239 for an 85% upside.GW Pharma’s consensus rating is a Strong Buy, based on a unanimous 6 buy ratings. The stock’s $223 average price target implies a premium of 73% from the current share price of $128.Visit TipRanks’ Analysts' Top Stocks, and find out which stocks have the full attention of Wall Street's best analysts.

  • Is GW Pharmaceuticals (GWPH) Outperforming Other Medical Stocks This Year?
    Zacks

    Is GW Pharmaceuticals (GWPH) Outperforming Other Medical Stocks This Year?

    Is (GWPH) Outperforming Other Medical Stocks This Year?

  • Neogen Forms Partnership With IGS to Enhance Beef Profile
    Zacks

    Neogen Forms Partnership With IGS to Enhance Beef Profile

    Neogen (NEOG), through the IGS partnership, aims to help cattle producers choose better cattle and enhance their productivity.

  • Medtronic Receives European Nod for Glucose Monitoring System
    Zacks

    Medtronic Receives European Nod for Glucose Monitoring System

    Medtronic (MDT) plans to upgrade diabetes care by combining technical advancement with better user experience.

  • Bull of the Day: GW Pharmaceuticals (GWPH)
    Zacks

    Bull of the Day: GW Pharmaceuticals (GWPH)

    Bull of the Day: GW Pharmaceuticals (GWPH)

  • Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line
    Zacks

    Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line

    Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.

  • Abbott Receives European Nod for Pediatric Heart Devices
    Zacks

    Abbott Receives European Nod for Pediatric Heart Devices

    Abbott (ABT) aims to offer better treatment options for the most vulnerable patient population.

  • Abbott Partners With Sanofi to Upgrade Diabetes Management
    Zacks

    Abbott Partners With Sanofi to Upgrade Diabetes Management

    Abbott (ABT) collaborates with Sanofi to revolutionize diabetes care through technological advancements.

  • The Zacks Analyst Blog Highlights: Anheuser-Busch, Fly Leasing, GW Pharmaceuticals, Nestl?? and Burberry
    Zacks

    The Zacks Analyst Blog Highlights: Anheuser-Busch, Fly Leasing, GW Pharmaceuticals, Nestl?? and Burberry

    The Zacks Analyst Blog Highlights: Anheuser-Busch, Fly Leasing, GW Pharmaceuticals, Nestl?? and Burberry

  • Why Investors Should Buy GW Pharmaceuticals Stock
    InvestorPlace

    Why Investors Should Buy GW Pharmaceuticals Stock

    Some call GW Pharmaceuticals (NASDAQ:GWPH) a cannabis company. Others, like GW Pharma CEO Justin Gover, believe it is a biotech company. Regardless of the industry in which the company operates, the important thing is that investors understand GW stock is an excellent long-term investment. Source: Shutterstock InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere's why. A Long Runway of GrowthCurrently, GW has one cannabis-derived drug, Epidiolex, that's available in the U.S. Another, Sativex, is in development, and there are several others in the pipeline that should make their way into the marketplace over the next several years. In the second quarter, Epidiolex generated net sales of $68.4 million, 204% higher than the drug's sales in the first quarter. Overall, GW's Q2 revenues were $72.0 million, 2,080% higher than a year earlier. * 7 Tech Stocks You Should Avoid Now GW began selling its cannabis-derived products in the U.S. in November 2018, and sales of its drugs in the largest European nations, France, Germany, and the U.K., are expected to begin later in 2019. Investment bank Evercore ISI predicts that U.S. peak sales of Epidiolex could be as high as $1.3 billion. Derived from a substance in cannabis called cannabidiol (CBD), Epidiolex is used to treat Dravet syndrome and Lennox-Gastaut syndrome, both of which are forms of childhood epilepsy. The fact that Epidiolex is the first FDA-approved medicine derived from cannabis has convinced many that GW is a marijuana stock. GW Isn't ProfitableLike many early-stage biotech companies, GW's expenses are high and its revenues are low. But the fact that it's generating meaningful revenue is certainly positive for GW stock. In the first six months of 2019, GW had an operating loss of $80.7 million, 46% lower than in the same period a year earlier. Once Epidiolex becomes available in Europe, GW's operating loss should drop much further. "In Europe, we are pleased to have recently received the positive opinion from (regulators) which clears the way for an expected approval in October," GW's CEO, Gover, was quoted as saying in an Aug. 6 press release. "Our European commercial organization is in place and will be ready to launch in the first European markets upon approval," he added. JPMorgan analyst Cory Kasimov raised his price target on GW stock by $18 in late August to $232. versus the $141 price at which GW stock closed on Friday. "A continued strong U.S. launch (of Epidiolex) and EU approval in October." along with the likely use of the drug to start treating Tuberous Sclerosis Complex in 2020, should enable GW stock to climb further, Kasimov stated in a note to clients. Tuberous Sclerosis Complex is a genetic disorder that results in noncancerous tumors spreading throughout the body. One of the side effects of the complex is epilepsy, which Epidiolex is intended to treat. The company estimates that as many as 80,000 Americans and as many as 2 million people worldwide are affected by TSC. The Bottom Line on GW StockAnother InvestorPlace columnist, Josh Enomoto, wrote something about GW stock in April that highlights the company's potential."In many ways, GWPH stock is the Amazon (NASDAQ:AMZN) of healthcare: their core ingredient, cannabis, is dirt cheap. Therefore, the underlying company has the ability to disrupt the drug-making industry like no one's business," Josh stated in an article published on April 30. As I see it, GW Pharmaceuticals is the best cannabis stock that isn't actually a cannabis stock. At the time of this writing Will Ashworth did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Recession-Resistant Services Stocks to Buy * 7 Hot Penny Stocks to Consider Now * 7 Tech Stocks You Should Avoid Now The post Why Investors Should Buy GW Pharmaceuticals Stock appeared first on InvestorPlace.

  • Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement
    Zacks

    Abbott's (ABT) FreeStyle Libre Gains Canadian Reimbursement

    With this reimbursement approval, Abbott's (ABT) FreeStyle Libre becomes the first sensor-based glucose monitoring system to be listed by any provincial health plan in Canada.

  • Medtronic (MDT) Earns Dow Jones Sustainability Recognition
    Zacks

    Medtronic (MDT) Earns Dow Jones Sustainability Recognition

    Medtronic's (MDT) strong ESG practices facilitate inclusion in the North American Dow Jones Sustainability Index.

  • Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes
    Zacks

    Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes

    Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.

  • CryoLife Enters Agreement With Endospan for Aortic Stent
    Zacks

    CryoLife Enters Agreement With Endospan for Aortic Stent

    CryoLife (CRY) eyes to expand the portfolio of aortic care, with endovascular stent graft system.

  • ECB Launches Fresh Stimulus! Grab 5 European Stocks Now
    Zacks

    ECB Launches Fresh Stimulus! Grab 5 European Stocks Now

    The ECB has unveiled a sweeping stimulus package in an attempt to prevent a sluggish Eurozone economy from grinding to a halt.

  • Benzinga

    Teva Dips Into Medical Marijuana Market With Canndoc Distribution Deal

    Cannabis companies have been feverishly stitching up partnerships with each other, beverage companies and biopharma companies to tap into the market's huge potential. Israel-based Teva Pharmaceutical Industries ...

  • Medical Cannabis: A Hot Topic at Events Across the World
    Market Realist

    Medical Cannabis: A Hot Topic at Events Across the World

    These days, experts are discussing the pros and cons of medical cannabis at multiple conferences and summits around the world.

  • Benzinga

    14 Top Cannabis Stocks Targeted By Short Sellers

    After a weak couple of months, cannabis stocks rallied in the first week of September . That rally seems to have stalled so far in the second week of the month. S3 Partners analyst Ihor Dusaniwsy said ...

  • Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring
    Zacks

    Baxter's (BAX) Cheetah Acquisition to Aid Patient Monitoring

    Baxter (BAX) expects this deal to remain neutral to its earnings in 2019 and 2020.